/IGC
IGC Stock - IGC Pharma, Inc.
Healthcare|BiotechnologyAMEX
$0.30-10.74%
$0.04 (-10.74%) • Dec 19
59
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.18
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.33
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IGC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.30 – $0.30
TARGET (TP)$0.34
STOP LOSS$0.28
RISK/REWARD1:2.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.25
52W High$0.50
52W Low$0.25
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.27M | $1.34M | $911,000 | $397,000 | $898,000 |
| Gross Profit | $619,000 | $733,000 | $-158,000 | $194,000 | $-349,000 |
| Gross Margin | 48.7% | 54.5% | -17.3% | 48.9% | -38.9% |
| Operating Income | $-7,446,000 | $-9,798,000 | $-11,571,000 | $-15,428,000 | $-8,724,000 |
| Net Income | $-7,121,000 | $-13,000,000 | $-11,506,000 | $-15,016,000 | $-8,811,000 |
| Net Margin | -560.3% | -966.5% | -1263.0% | -3782.4% | -981.2% |
| EPS | $-0.09 | $-0.22 | $-0.22 | $-0.30 | $-0.21 |
Company Overview
IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
IGCBeat Rate
38%
Last 8 quarters
Avg Surprise
-118.4%
EPS vs Estimate
Beats / Misses
3/4
1 met exactly
Latest EPS
$-0.02
Q4 2025
EPS Surprise History
Q1 24
-125.0%
$-0.09vs$-0.04
Q2 24
-900.0%
$-0.04vs$-0.00
Q3 24
-15.9%
$-0.03vs$-0.03
Q4 24
-23.1%
$-0.02vs$-0.02
Q1 25
+33.3%
$-0.02vs$-0.03
Q2 25
+50.0%
$-0.01vs$-0.02
Q3 25
+33.3%
$-0.02vs$-0.03
Q4 25
0.0%
$-0.02vs$-0.02
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 13, 2026 | $-0.02 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.02 | $-0.02 | 0.0% | = MET |
Q3 2025 | Aug 14, 2025 | $-0.03 | $-0.02 | +33.3% | ✓ BEAT |
Q2 2025 | Jun 27, 2025 | $-0.02 | $-0.01 | +50.0% | ✓ BEAT |
Q1 2025 | Feb 14, 2025 | $-0.03 | $-0.02 | +33.3% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.02 | $-0.02 | -23.1% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.03 | $-0.03 | -15.9% | ✗ MISS |
Q2 2024 | Jun 24, 2024 | $-0.00 | $-0.04 | -900.0% | ✗ MISS |
Q1 2024 | Feb 14, 2024 | $-0.04 | $-0.09 | -125.0% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | — | $-0.05 | — | — |
Q3 2023 | Jul 7, 2023 | — | $-0.08 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.13 | — | — |
Q1 2023 | Feb 14, 2023 | — | $-0.04 | — | — |
Q4 2022 | Nov 1, 2022 | — | $-0.05 | — | — |
Q3 2022 | Aug 8, 2022 | — | $-0.05 | — | — |
Q2 2022 | Jun 22, 2022 | — | $-0.13 | — | — |
Q1 2022 | Feb 10, 2022 | — | $-0.05 | — | — |
Q4 2021 | Oct 29, 2021 | — | $-0.09 | — | — |
Q3 2021 | Aug 11, 2021 | — | $-0.04 | — | — |
Q2 2021 | Jun 14, 2021 | — | $-0.07 | — | — |
Latest News
IGC Pharma Gets New Patent From U.S. Patent And Trademark Office To Treat Stuttering, Tourette's Syndrome
📈 PositiveBenzinga•Dec 19, 2025, 02:02 PM
U.S. Centers For Medicare & Medicaid Services Administrator Says Millions Of Americans On Medicare To Become Eligible To Receive CBD As Early As April
📈 PositiveBenzinga•Dec 18, 2025, 06:59 PM•Also: , ,
Trump Order Will Direct Maintaining Restrictions On Dangerous Products; Centers For Medicare & Medicaid Services Plans To Allow Beneficiaries To Benefit From Hemp-derived Cbd Products At No Cost; Trump Order Will Not Encourage Use, But Recognizes Potential Both Therapeutic Uses And Risks Like Addiction; Marijuana Will Remain Illegal To Possess Under Federal Law; Trump Order Makes No Changes To Criminal Penalties Or Access For Recreational Use Of Marijuana
➖ NeutralBenzinga•Dec 18, 2025, 06:51 PM•Also: , ,
'Trump Expected To Sign An Order Moving To Reclassify Cannabis And Open Up Medical Potential' - NBC News
📈 PositiveBenzinga•Dec 17, 2025, 09:12 AM•Also: , ,
IGC Pharma Increases Authorized Common Stock To 600M Shares
📉 NegativeBenzinga•Dec 15, 2025, 09:22 PM
Liz Claman Posts On X "ALERT: Word is a @realDonaldTrump executive order to reclassify cannabis/marijuana as less dangerous, less regulated Class III substance
📈 PositiveBenzinga•Dec 15, 2025, 08:48 PM•Also: , ,
President Trump Says Considering Executive Oder To Reclassify Marijuana
➖ NeutralBenzinga•Dec 15, 2025, 08:45 PM•Also: , ,
IGC Pharma Highlights AI-Driven Alzheimer's Drug Development Amid Federal Cannabis Schedule III Reclassification Momentum
📈 PositiveBenzinga•Dec 15, 2025, 02:07 PM
Shares of cannabis-linked stocks are trading higher following a report suggesting that President Trump is expected to reclassify marijuana as a Schedule III drug.
📈 PositiveBenzinga•Dec 12, 2025, 01:23 PM•Also: , ,
IGC Pharma Reaches Key Enrollment Milestone Of 65% For Ongoing Phase 2 CALMA Clinical Trial Evaluating IGC-AD1 For Treatment Of Agitation In Alzheimer's Disease
📈 PositiveBenzinga•Dec 9, 2025, 02:01 PM
'Nebraska Supreme Court Hears Case Seeking To Overturn Medical Marijuana Law Approved By Voters' - Marijuana Moment
➖ NeutralBenzinga•Dec 4, 2025, 01:59 PM•Also: , ,
IGC Pharma Highlights Publication Of Caregiver Book On Alzheimer's Disease
➖ NeutralBenzinga•Dec 2, 2025, 02:02 PM
UPDATE: 'Medicare to Test Making CBD Treatment Available for Seniors' - Bloomberg News
📈 PositiveBenzinga•Nov 26, 2025, 05:58 PM•Also: , ,
'Marijuana Banking Bill Is 'On The Back Burner,' As Congressional Lawmakers See No Indication It'll Advance Soon' - Marijuana Moment
📉 NegativeBenzinga•Nov 25, 2025, 03:27 PM•Also: , ,
'GOP Representative Brian Mast Signs On As Sponsor Of Bipartisan Legislation To Reschedule Cannabis' - Marijuana Herald
📈 PositiveBenzinga•Nov 24, 2025, 04:19 PM•Also: , ,
IGC Pharma Q2 EPS $(0.02), Inline, Sales $191.000K Miss $325.000K Estimate
📉 NegativeBenzinga•Nov 17, 2025, 01:38 PM
IGC Pharma Granted Patent From USPTO For Propriety Formulation Used In IGC-AD1 Drug Candidate For Agitation In Alzheimer's Disease
📈 PositiveBenzinga•Nov 13, 2025, 02:04 PM
IGC Pharma Will Be Issued U.S. Patent Number 12,465,589 Tomorrow Titled "METHOD AND COMPOSITION FOR TREATING CNS DISORDERS (SPECIFICALLY ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE)"
📈 PositiveBenzinga•Nov 10, 2025, 09:50 PM
IGC Pharma Expands AI-Powered In-Silico Platform To Accelerate Alzheimer's Drug Discovery
📈 PositiveBenzinga•Nov 3, 2025, 01:56 PM
IGC Pharma Expands Ongoing Phase 2 CALMA Clinical Trial Evaluating Investigational Drug Candidate IGC-AD1 For Agitation In Alzheimer's Disease
📈 PositiveBenzinga•Oct 14, 2025, 01:02 PM
Frequently Asked Questions about IGC
What is IGC's current stock price?
IGC Pharma, Inc. (IGC) is currently trading at $0.30 per share. The stock has moved -10.74% today.
What is the analyst price target for IGC?
No analyst price targets are currently available for this stock.
What sector is IGC Pharma, Inc. in?
IGC Pharma, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the AMEX exchange.
What is IGC's market cap?
IGC Pharma, Inc. has a market capitalization of $0.03 billion, making it a small-cap company.
Does IGC pay dividends?
No, IGC Pharma, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANTX
AN2 Therapeutics, Inc.
$1.12
Mkt Cap: $0.0B
BOLD
Boundless Bio, Inc.
$1.22
Mkt Cap: $0.0B
INTS
Intensity Therapeutics, Inc.
$0.41
Mkt Cap: $0.0B
ITRM
Iterum Therapeutics plc
$0.37
Mkt Cap: $0.0B
NTRB
Nutriband Inc.
$4.49
Mkt Cap: $0.1B
NXTC
NextCure, Inc.
$11.38
Mkt Cap: $0.0B
PLUR
Pluri Inc.
$3.40
Mkt Cap: $0.0B
PSTV
Plus Therapeutics, Inc.
$0.57
Mkt Cap: $0.0B
QTTB
Q32 Bio Inc.
$2.96
Mkt Cap: $0.0B
SABS
SAB Biotherapeutics, Inc.
$3.99
Mkt Cap: $0.0B
Explore stocks similar to IGC for comparison